Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors

James G. Drougas, Lowell B. Anthony, Taylor K. Blair, Richard R. Lopez, J. Kelly Wright, William C. Chapman, Laura Webb, Murray Mazer, Steven Meranze, C. Wright Pinson

Research output: Contribution to journalArticlepeer-review

113 Scopus citations

Abstract

BACKGROUND: Patients with advanced metastatic carcinoid tumors who have disease progression despite conventional therapy are left with few therapeutic options. Hepatic artery chemoembolization (HACE) may play a role in palliating these patients' symptoms. METHODS: Fifteen patients with biopsy-proven advanced bilobar hepatic carcinoid metastases who demonstrated progression of symptoms and/or tumor size despite treatment with somatostatin analogues were treated with intra-arterial chemotherapy and HACE to determine efficacy and safety. Five days of intra-arterial 5-fluorouracil (1 g/m2) were followed by HACE with adriamycin (60 mg), cisplatin (100 mg), mitomycin C (30 mg), and polyvinyl alcohol (Ivalon); 200μ to 710 μ). Patients were continued on octreotide at the same dose (150 to 2000 μg subcutaneous q 8 hours) before, during, and after the procedure. RESULTS: Efficacy of treatment was assessed by comparing pretreatment and 3-month clinical, laboratory, radiographic, and quality of life parameters. Symptoms were improved in 8 of 12 patients who had diarrhea, 7 of 12 who had flushing, 9 of 12 who had abdominal pain, and in 4 of 7 who had malaise. Elevated tumor markers decreased in all patients. Biochemical markers (mean ± SE) at 3 months decreased by 60% ± 6% for 5-HIAA, 75% ± 10% for chromogranin A and 50% ± 7% for neuron-specific enolase. Tomographic assessment revealed tumor liquefaction in 10 of 13 patients. The Karnofsky performance status improved from a mean of 66 ± 2 to 84 ± 2 (P <0.001). Median follow-up was 16 months, with 13 deaths occurring from I week to 71 months after treatment. CONCLUSIONS: Hepatic artery chemoembolization improves symptoms of carcinoid syndrome, has a high tumor response rate, and improves short-term quality of life in this group of patients with advanced hepatic carcinoid disease.

Original languageEnglish
Pages (from-to)408-412
Number of pages5
JournalAmerican journal of surgery
Volume175
Issue number5
DOIs
StatePublished - May 21 1998
Externally publishedYes

Fingerprint Dive into the research topics of 'Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors'. Together they form a unique fingerprint.

Cite this